Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 1536489A

Drug Profile

GSK 1536489A

Alternative Names: FluLaval; FluLaval trivalent; FluLaval-YB; FluSF; Fluviral; Fluviral-S-F; Fluviral-S/F; GSK-1536489A; GSK-1557482A; Influenza vaccine split virion inactivated - GlaxoSmithKline; SPD-707

Latest Information Update: 31 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ID Biomedical Corporation
  • Developer Folia Biotech; GlaxoSmithKline; ID Biomedical Corporation; Pan-Provincial Vaccine Enterprise
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 02 Oct 2019 Safety and immunogenicity data from a phase I trial in Influenza virus infections presented at the IDWeek (IDW-2019)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention, Adjuvant therapy) in Canada (IM, Injection)
  • 01 Apr 2014 Phase-I clinical trials in Influenza virus infections (adjuvant therapy, prevention) in Canada (IM)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top